


Information FOR HEALTH PROFESSIONALS



ASCIA treatment guideline for chronic spontaneous urticaria (Australia)

Whilst the pathway shaded in green is approved by TGA/PBS, ASCIA recommends that some patients may benefit from omalizumab who have a lower UAS, as supported by clinical trial data.

* Note: H2 antagonists are now difficult to source and the evidence base for efficacy in chronic spontaneous urticaria is weak, so ASCIA recommends a treatment trial of high dose antihistamines in combination with montelukast, before applying for omalizumab.



If responding to omalizumab:

Consider reducing the dose if there is a response after 6 months

- 3 month trial 150mg monthly
- trial cessation; provision to recommence if recurrence (UAS ≥16)

© ASCIA 2020